IRIS UniCatt

Nero, Camilla
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.539
AS - Asia 2.206
EU - Europa 1.683
SA - Sud America 457
AF - Africa 53
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.947
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.427
SG - Singapore 993
IT - Italia 541
CN - Cina 441
BR - Brasile 360
DE - Germania 242
SE - Svezia 240
VN - Vietnam 225
FR - Francia 137
HK - Hong Kong 120
IN - India 114
GB - Regno Unito 103
IE - Irlanda 85
FI - Finlandia 79
ID - Indonesia 64
JP - Giappone 61
UA - Ucraina 60
NL - Olanda 48
CA - Canada 46
RU - Federazione Russa 38
BD - Bangladesh 35
MX - Messico 32
AR - Argentina 31
KR - Corea 29
AT - Austria 21
IQ - Iraq 19
PL - Polonia 19
BE - Belgio 17
EC - Ecuador 16
ES - Italia 15
TR - Turchia 15
PH - Filippine 14
ZA - Sudafrica 14
IR - Iran 11
MA - Marocco 11
CO - Colombia 10
PK - Pakistan 10
CL - Cile 9
VE - Venezuela 9
SA - Arabia Saudita 8
PE - Perù 7
PY - Paraguay 7
UZ - Uzbekistan 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
HN - Honduras 6
IL - Israele 6
JO - Giordania 6
JM - Giamaica 5
KG - Kirghizistan 5
CH - Svizzera 4
KE - Kenya 4
KZ - Kazakistan 4
LT - Lituania 4
MY - Malesia 4
NG - Nigeria 4
RO - Romania 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
GT - Guatemala 3
HU - Ungheria 3
LB - Libano 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
TN - Tunisia 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
AW - Aruba 2
BO - Bolivia 2
DZ - Algeria 2
GF - Guiana Francese 2
HR - Croazia 2
MD - Moldavia 2
MN - Mongolia 2
PR - Porto Rico 2
SI - Slovenia 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
DM - Dominica 1
GE - Georgia 1
GI - Gibilterra 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
Totale 6.940
Salva come PNG Salva come JPEG
Città #
Singapore 574
Ashburn 303
San Jose 303
Chandler 272
Rome 202
Hong Kong 110
New York 101
Beijing 99
Dublin 80
Los Angeles 72
Ho Chi Minh City 71
Hefei 68
Hanoi 63
The Dalles 60
Milan 58
Hyderabad 57
Tokyo 56
Ann Arbor 54
Jakarta 53
Lauterbourg 52
Frankfurt am Main 42
Columbus 41
Munich 41
St Louis 41
Helsinki 40
San Mateo 40
Dallas 36
Council Bluffs 35
São Paulo 34
Boardman 33
Boston 31
Wilmington 30
Jacksonville 28
Santa Clara 27
Nanjing 23
Orem 23
Seoul 23
Moscow 22
Princeton 20
Buffalo 19
Cattolica 19
Kent 19
Atlanta 18
Marseille 18
Dearborn 17
Nuremberg 16
Rio de Janeiro 16
Vienna 16
London 15
Bari 14
Brooklyn 14
Brussels 14
Houston 14
Turku 14
Amsterdam 13
Chicago 13
Lappeenranta 13
North Bergen 13
Toronto 13
Montreal 12
Paris 12
Phoenix 12
Stockholm 12
Warsaw 12
Bexley 11
Fairfield 11
Lawrence 11
Mexico City 11
Nürnberg 11
Johannesburg 10
Seattle 10
Washington 10
Denver 9
Leawood 9
Shanghai 9
Woodbridge 9
Baghdad 8
Brasília 8
Düsseldorf 8
Poplar 8
Redwood City 8
Bologna 7
Bremen 7
Chennai 7
Da Nang 7
Newark 7
San Francisco 7
Vancouver 7
Abidjan 6
Amman 6
Campinas 6
Dhaka 6
Fortaleza 6
Guangzhou 6
Querétaro 6
Quito 6
Roubaix 6
Tashkent 6
Turin 6
Andover 5
Totale 3.967
Salva come PNG Salva come JPEG
Nome #
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 210
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. 183
Privacy in Italian Clinical Reports: A NLP-Based Anonymization Approach 178
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 176
A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment 174
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids 157
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience 155
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 147
Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer 144
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 142
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 142
Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer 140
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 138
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 135
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes 133
Targeting the hallmarks of ovarian cancer: The big picture 132
Pd-l1 expression on circulating tumour-derived microvesicles as a complementary tool for stratification of high-grade serous ovarian cancer patients 131
Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study 127
Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY) 126
A cost-effectiveness analysis of an integrated clinical-radiogenomic screening program for the identification of BRCA 1/2 carriers (e-PROBE study 126
Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center 126
One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer 125
Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer 124
Radiomics analysis of ultrasound images to discriminate between benign and malignant adnexal masses with solid morphology on ultrasound 123
Laparoscopic Management of a Small Bowel Recurrence of Endometrial Cancer 121
Recent progress in the use of pharmacotherapy for endometrial cancer 118
PARP Inhibitors Resistance: Mechanisms and Perspectives 117
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 117
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 116
Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications 116
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 116
Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience 112
Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience 111
Advanced and recurrent endometrial cancer: State of the art and future perspectives 110
Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: Prognostic role and clinical considerations 109
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 109
Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study 108
Sentinel-node biopsy in early stage ovarian cancer: a prospective multicentre study (SELLY) 106
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 103
Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study) 102
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 96
Robotic Splenectomy for Isolated Splenic Recurrence of Endometrial Adenocarcinoma 96
Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye 94
Newly diagnosed ovarian cancer: Which first-line treatment? 94
Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety 93
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 92
Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY) 90
L1CAM Expression in Microcystic, Elongated, and Fragmented (MELF) Glands Predicts Lymph Node Involvement in Endometrial Carcinoma 87
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres 86
Radiomics and Radiogenomics of Ovarian Cancer: Implications for Treatment Monitoring and Clinical Management 85
Laparoscopic Splenectomy for Secondary Cytoreduction in Ovarian Cancer Patients With Localized Spleen Recurrence: Feasibility and Technique 81
Management of stage III and IVa uterine cancer 73
Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors 72
Electronic nose-based volatile organic compound profiling in gynecologic oncology: current evidence and diagnostic accuracy 71
Minilaparoscopic Aortic Lymphadenectomy 71
Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy 69
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 64
Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations 63
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 47
Image-guided real-time optical biopsy in oncologic surgery: a systematic review of the role of confocal microscopy in the era of digital surgery 44
Circulating tumor DNA in endometrial cancer: clinical significance and implications 41
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer 29
Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis 29
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib 15
Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers 12
Patient-derived organoids in renal cell carcinoma: A review of methodologies and applications 9
A review of reviews of the prevalence of molecular biomarkers in vulvar cancer and their implications for prognosis refinement and treatment strategies 8
Focal lymphovascular space invasion: Friend or foe? A large retrospective analysis on stage I endometrioid endometrial carcinomas 8
Unraveling Tumor Heterogeneity in Gynecological Cancer Using a Radiogenomics Approach 6
Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers 6
Integration of PARP-inhibitors in ovarian cancer therapy 6
Developing and validating ultrasound-based machine-learning models incorporating radiomics features to predict malignancy in adnexal masses 6
Varan: a tool for managing mutational data and creating cancer studies in cBioPortal 5
Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data 5
A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease 5
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions 5
A comparative analysis of tumor markers reveals EDA fibronectin as a promising target in high-grade serous ovarian cancer 4
Identification of a False-positive Multiplex Ligation-dependent Probe Amplification Result in BRCA1 Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay 4
Correction to: Uterine cellular leiomyoma with a novel HMGA2::PLCZ1 fusion and aberrant cyclin D1 expression: expanding the molecular spectrum and highlighting a diagnostic pitfall (Virchows Archiv, (2026), 10.1007/s00428-025-04387-w) 4
PTEN and gynecological cancers 4
Ovarian cancer treatments strategy: Focus on parp inhibitors and immune check point inhibitors 4
Immunotherapy in gynecological cancers 4
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 3
Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how 3
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer 3
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives 3
Future of sentinel node biopsy in ovarian cancer 3
Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy 3
Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping review 2
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC 2
Decoding tumor evolution in advanced ovarian cancer: Proteogenomic insights before and after neoadjuvant chemotherapy 2
Sentinel lymph node biopsy in ovarian cancer: More questions than certainties 2
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 2
ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study 2
Key issues in diagnostic accuracy of sentinel lymph node biopsy in early-stage ovarian cancer: systematic review and meta-analysis 2
BRCA2 and genetic mutations in prostate cancer: an updated practical guide on “when and how” testing across international guidelines 2
Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study 2
Enhanced Detection of BRCA Copy Number Alterations Within a Commercial HRD Assay: Implications for Precision Oncology in Ovarian Cancer 2
Comprehensive genomic profiling and clinico-pathologic characterization of primary ovarian leiomyosarcoma 1
Prediction of germline BRCA 1/2 genes pathogenetic variants from ultrasound images of healthy ovaries: Radiogenomics as an innovative tool to prevent BRCA-related cancers (PROBE II) 1
Totale 7.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 0 7
2021/2022312 12 13 4 24 18 5 15 55 15 27 49 75
2022/2023737 93 96 52 115 37 91 34 53 74 16 32 44
2023/2024523 12 116 23 47 26 57 43 33 5 30 65 66
2024/20251.350 39 28 96 60 91 63 63 50 153 168 311 228
2025/20263.677 391 225 224 420 562 197 561 198 261 266 267 105
Totale 7.116